Comparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease. (PubMed, Diabetes Obes Metab) - Sep 18, 2026 - "SGLT2i showed the broadest cardiorenal benefits, while finerenone and semaglutide provided additional protection across selected outcomes. Finerenone increased hyperkalaemia and treatment discontinuation. The efficacy of finerenone-SGLT2i combination therapy requires further investigation."
Journal • Cardiovascular • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus
|
|
Dan Chen; Gaosi Xu; Linghua Fu; Peng Yu; Pingping Yang; Qinghua Wu; Tao Wu; Ziyan Zhou
|